Lars Bullinger

发表

Netboost: Boosting-supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington's Disease.

Harald Binder, Pascal Schlosser, Jochen Knaus, 2020, IEEE/ACM transactions on computational biology and bioinformatics.

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

Claudio Lottaz, Stefan Fröhling, Jonathan R Pollack, 2007 .

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

Lars Bullinger, Andrew L Kung, Scott A Armstrong, 2011, Cancer cell.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Manuela Zucknick, Verena I Gaidzik, Lars Bullinger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Axel Benner, Stefan Fröhling, Lars Bullinger, 2008, The New England journal of medicine.

Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization.

Stefan Fröhling, Bernhard Radlwimmer, Peter Lichter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.

Lars Bullinger, Hartmut Döhner, Konstanze Döhner, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia

Fatima Al-Shahrour, Rudolf Jaenisch, Stefan Fröhling, 2010, Nature Medicine.

Repressing the repressor: A new mode of MYC action in lymphomagenesis

Lars Bullinger, L. Bullinger, T. Wirth, 2009, Cell cycle.

Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice.

Axel Benner, Peter Lichter, Lars Bullinger, 2002, Blood.

Precision oncology for acute myeloid leukemia using a knowledge bank approach

Inigo Martincorena, Verena I Gaidzik, Peter J Campbell, 2017, Nature Genetics.

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.

Robert Tibshirani, Stefan Fröhling, Jonathan R Pollack, 2008, Blood.

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes

Sören Lehmann, Andreas Lennartsson, Verena I Gaidzik, 2014, Epigenetics.

Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients.

Anders Krogh, Ole Winther, Frederik Otzen Bagger, 2014, Blood.

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

Lars Bullinger, Christian Buske, Wolfgang Hiddemann, 2012, Blood.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases

Martin Dugas, Torsten Haferlach, Lars Bullinger, 2008 .

SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma

Christian Langer, Bernhard Kuster, Michele Pagano, 2012, Nature Cell Biology.

Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.

Michael Heuser, Lars Bullinger, Brigitte Schlegelberger, 2005, Haematologica.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Martin Glas, Michael Sabel, Jörg-Christian Tonn, 2019, The Lancet.

Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling

Axel Benner, Harald Binder, Martin Schumacher, 2016, PloS one.

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

Axel Benner, Peter Lichter, Lars Bullinger, 2007, Haematologica.

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Verena I Gaidzik, Lars Bullinger, Hartmut Döhner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A 17-gene stemness score for rapid determination of risk in acute leukaemia

Claude Preudhomme, Peter W. Zandstra, Bob Löwenberg, 2016, Nature.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Ulrich Mansmann, Xinan Yang, Guido Marcucci, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Verena I Gaidzik, Michael Heuser, Lars Bullinger, 2019, Nature Communications.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Stefan Fröhling, Lars Bullinger, Claudia Scholl, 2005, Blood.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia

Lars Bullinger, Hans A Kestler, Hartmut Döhner, 2011, Haematologica.

Low-grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging: Results of a Multicenter Retrospective Assessment of the German Study Group for Intraoperative Magnetic Resonance Imaging.

Oliver Ganslandt, Christian Rainer Wirtz, Sotirios Bisdas, 2016, Neurosurgery.

Clonal Evolution in Chronic Lymphocytic Leukemia: Acquisition of High-Risk Genomic Aberrations Associated with Unmutated VH, Resistance to Therapy, and Short Survival.

Axel Benner, Peter Lichter, Lars Bullinger, 2006 .

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

David A. Williams, Lars Bullinger, Rebecca Austin, 2014, Cell stem cell.

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Sridhar Ramaswamy, D. Gary Gilliland, Pablo Tamayo, 2009, Cell.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.

t(11;14)‐positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B‐cell chronic lymphocytic leukemia

Michael Baudis, Peter Lichter, Peter Möller, 2000, Genes, chromosomes & cancer.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.